

Liven Pharma Limited
STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	5	918,164,718	666,512,380
Intangible assets	6	4,796,922	8,440,679
Total non-current assets		922,961,640	674,953,059
CURRENT ASSETS			
Trade debts	7	11,115,542	9,402,578
Stock in trade	8	92,902,365	123,324,881
Tax refund due from Government	9	733,459	-
Prepayments, deposits and advances	10	6,777,661	7,339,727
Short term investments	11	163,300,000	-
Cash and bank balances	12	18,250,894	7,884,396
Total current assets		293,079,921	147,951,582
TOTAL ASSETS		1,216,041,561	822,904,641
EQUITY AND LIABILITIES			
Share capital and reserves			
Share capital			
Issued, subscribed and paid-up share capital	13	1,130,403,670	930,403,670
Capital reserve			
Surplus on revaluation on property, plant and equipment	14	188,911,397	-
Revenue reserve			
Accumulated loss		(333,857,053)	(296,543,276)
Total equity		985,458,014	633,860,394
LIABILITIES			
NON-CURRENT LIABILITIES			
Lease liabilities	15	2,338,379	1,247,868
Long term financing	16	2,520,472	5,098,065
Deferred taxation	17	114,451,738	92,272,765
Total non-current liabilities		119,310,589	98,618,698
CURRENT LIABILITIES			
Trade and other payables	18	82,390,515	61,720,121
Loan from related parties	19	15,282,580	14,047,263
Running finance	20	9,117,046	11,185,166
Mark up accrued	21	304,745	386,020
Current portion of long term liabilities	22	4,178,072	3,086,979
Provision for taxation	23	-	-
Total current liabilities		111,272,958	90,425,549
Total liabilities		230,583,547	189,044,247
TOTAL EQUITY AND LIABILITIES		1,216,041,561	822,904,641
CONTINGENCIES AND COMMITMENTS	24		

The annexed notes 1 to 49 form an integral part of these financial statements.

Rabir

[Signature]
 Chief Executive

[Signature]
 Director

[Signature]
 Chief Financial Officer

Liven Pharma Limited
STATEMENT OF PROFIT OR LOSS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
Sales	25	105,806,555	127,271,949
Cost of sales	26	(79,160,938)	(109,313,168)
Gross profit		26,645,617	17,958,781
Administrative and general expenses	27	(37,712,939)	(373,563,504)
Selling and distribution expenses	28	(9,761,800)	(17,606,673)
Other expenses	29	(53,771,704)	(116,904,602)
Finance costs	30	(2,539,511)	(785,675)
Operating loss		(77,140,337)	(490,901,673)
Other income	31	12,218,820	305,814
Loss before levies and taxation		(64,921,517)	(490,595,859)
Levies	32	(1,399,506)	(1,590,899)
Loss before taxation		(66,321,023)	(492,186,758)
Taxation	33	35,182,336	(92,272,765)
Loss after taxation		(31,138,687)	(584,459,523)
Loss per share - Basic and diluted (restated)	34	(0.28)	(7.11)

The annexed notes 1 to 49 form an integral part of these financial statements.

Army




Chief Executive




Director




Chief Financial Officer

Liven Pharma Limited

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED JUNE 30, 2026


	Note	2026 (Rupees)	2025 (Rupees)
Loss after taxation		(31,138,687)	(584,459,523)
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss (net of tax):		-	-
Items that will not be reclassified to profit or loss (net of tax):			
Surplus on revaluation on property, plant and equipment		188,911,397	-
Total other comprehensive income for the year		188,911,397	-
Total comprehensive income/(loss) for the year		<u>157,772,710</u>	<u>(584,459,523)</u>

The annexed notes 1 to 49 form an integral part of these financial statements.

Attested



 Chief Executive



 Director



 Chief Financial Officer

Liven Pharma Limited
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED JUNE 30, 2026


	Share capital	Capital reserve	Revenue reserve	Total equity
Particulars	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated (loss)/profit	
Rupees				
Balance as at July 01, 2024	400,000	589,507,658	159,784,726	749,692,384
Effect of scheme of arrangement/ merger (note 1.2)	-	(461,376,137)	-	(461,376,137)
Transfer to retained earnings	-	(128,131,521)	128,131,521	-
Transactions with owners:				
Deemed issued during the year	121,237,000	-	-	121,237,000
Issued against loan to directors	142,500,000	-	-	142,500,000
Issued as a result of merger scheme	666,666,670	-	-	666,666,670
Adjustment of share capital of LPL	(400,000)	-	-	(400,000)
	930,003,670	-	-	930,003,670
Comprehensive income for the year:				
Loss for the year	-	-	(584,459,523)	(584,459,523)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the year	-	-	(584,459,523)	(584,459,523)
Transfer to accumulated loss on account of incremental depreciation (net of tax)	-	-	-	-
Balance as at June 30, 2025	930,403,670	-	(296,543,276)	633,860,394
Balance as at July 01, 2025	930,403,670	-	(296,543,276)	633,860,394
Transactions with owners:				
Issuance of right shares	200,000,000	-	-	200,000,000
Share issuance cost - net of tax	-	-	(6,175,090)	(6,175,090)
	200,000,000	-	(6,175,090)	193,824,910
Comprehensive income for the year:				
Loss for the year	-	-	(31,138,687)	(31,138,687)
Other comprehensive income	-	188,911,397	-	188,911,397
Total comprehensive income for the year	-	188,911,397	(31,138,687)	157,772,710
Transfer to accumulated loss on account of incremental depreciation (net of tax)	-	-	-	-
Balance as at June 30, 2026	1,130,403,670	188,911,397	(333,857,053)	985,458,014

The annexed notes 1 to 49 form an integral part of these financial statements.

R. Khurana



Chief Executive



Director



Chief Financial Officer

Liven Pharma Limited
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before taxation		(66,321,023)	(492,186,758)
Adjustments for non cash and other items:			
Depreciation on property, plant and equipment	5.5	26,088,954	23,276,063
Depreciation on right of use assets	5.6	1,112,405	1,394,478
Amortization on intangible assets	6.2	3,643,757	2,963,319
Listing expense	27.1	-	327,803,230
Bad debt written off	29	-	29,658,026
Allowance for expected credit loss	29	11,582,140	87,214,758
Provision for impairment on advance to supplier	29	5,160,109	-
Gain on sale of property, plant and equipment	31	(4,665,920)	-
Provision for obsolete stock	29	36,760,211	-
Workers' welfare fund (WWF) payable	29	26,452	31,818
Additional charge on unpaid balance of WWF	30	4,773	-
Finance costs	30	2,534,738	785,675
Operating profit / (loss) before working capital changes		15,926,596	(19,059,391)
Working capital changes			
Decrease / (increase) in current assets:			
Stock in trade		(6,337,695)	458,856
Trade debts		(13,295,104)	(21,524,966)
Prepayments, deposits and advances		(4,598,043)	(522,090)
(Decrease) / increase in current liabilities:			
Trade and other payables		20,639,169	39,396,735
Cash generated from / (used in) from operations	A	12,334,923	(1,250,855)
Finance costs paid		(2,616,013)	(473,655)
Taxes paid		(733,459)	-
Net cash generated from / (used) in operating activities		8,985,451	(1,724,510)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments against acquisition of property, plant and equipment		(29,661,895)	(22,836,069)
Proceeds from disposal of property, plant and equipment		7,148,500	-
Payments against acquisition of intangible asset		-	(10,000,000)
Purchase of short term investments		(646,572,000)	-
Proceeds of disposal of short term investments		483,272,000	-
Net cash used in investing activities	B	(185,813,395)	(32,836,069)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payments against lease liabilities		(697,852)	(1,357,822)
Proceeds from issuance of right shares		200,000,000	-
Payments against transaction cost for issuance of right issue		(8,697,310)	-
Proceeds from loan from director		1,643,465	14,047,263
Repayments of loan from director		(408,148)	-
Proceeds from running finance		90,779,215	154,672,254
Repayments against running finance		(92,847,335)	(156,143,152)
Proceeds from long term finance		-	6,680,000
Repayments against long term finance		(2,577,593)	(441,679)
Net cash generated from financing activities	C	187,194,442	17,456,864
Net increase/(decrease) in cash and cash equivalents	A+B+C	10,366,498	(17,103,715)
Cash and cash equivalents acquired as a result of merger		-	32,782
Cash and cash equivalents at the beginning of the period		7,884,396	24,955,329
Cash and cash equivalents at the end of the period	12.1	18,250,894	7,884,396

The annexed notes 1 to 49 form an integral part of these financial statements.

Rohay

Luqman
 Chief Executive
 C.E.O.

Fazal
 Director
 Director

Shah
 Chief Financial Officer
 C.F.O.